Dr. Wahl studied biochemistry at the University of Hannover from 2002 to 2007. He later joined the Institute of Immunology of the Hannover Medical School, where he received his Ph.D. in 2011. His research as a post-doctoral fellow mainly focused on the inspection of mice and human T cell and B cell repertoires based on next-generation sequencing (NGS) data analysis. Dr. Wahl joined GATC Biotech’s R&D team in 2012. His main tasks involve the establishment and optimisation of laboratory workflows, particularly for the fields of plasma cell-free DNA and epigenetics. Dr. Wahl is a main contributor of scientific data to a range of publicly funded projects, including EpiFemCare, KlebsiCure and FORECEE.
Next-generation sequencing